Introduction {#S0001}
============

Hepatocellular carcinoma (HCC) is the fifth most frequent cancer worldwide and is also the third leading cause of cancer-related mortality \[[@CIT0001], [@CIT0002]\]. The World Health Organisation (WHO) has estimated that there are nearly 56,400 new cases of HCC around the world per year \[[@CIT0003]\], and the incidence is much higher in men than in women. The highest liver cancer rates are found in developing countries, especially in East Asia and Malaysia, South Africa, and Sub-Saharan Africa, whereas rates are lower in Europe, North and South America, Australia, and New Zealand \[[@CIT0004]\]. HCC can be induced by several risk factors, such as chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV), hepatic cirrhosis, alcoholic liver disease, and exposure to aflatoxins \[[@CIT0005]--[@CIT0007]\].

Hepatocellular carcinoma always results from accumulative, long-term interactions between environmental and genetic factors. The multifactorial progression of HCC involves the activation of oncogenes, the inactivation of tumour suppressor genes, gene mutations, and irreversible cell damage. Many studies have focused on the genetic mutations and the overexpression of abnormal genes that promote malignant progression, such as Cyclin D1 (CCND1), v-raf murine sarcoma viral oncogene homolog B (BRAF), epidermal growth factor receptor (EGFR), c-myc, Ras, AKT, Yap, and baculoviral IAP repeat containing 2 (BIRC2) \[[@CIT0008], [@CIT0009]\], as well as on the deletion or loss of heterozygosity (LOH) in the chromosomal regions of tumour suppressor genes, such as CDKN2A, RB1, TP53, and PTEN \[[@CIT0009], [@CIT0010]\].

Although many genes that can promote or suppress HCC have been identified, the molecular mechanisms underlying HCC initiation, progression, metastasis, or targeted therapy remain unclear. High-throughput microarray technology, which enables investigators to obtain massive expression data sets, has been demonstrated to be a useful approach for identifying new tumour marker genes for tumour diagnosis or targeted treatment \[[@CIT0011]--[@CIT0013]\].

The aim of this study was to analyse the expression profile of hepatocellular carcinoma compared with normal liver by using bioinformatics methods.

Material and methods {#S0002}
====================

Affymetrix microarray data from hepatocellular carcinoma and adjacent normal liver tissues {#S20003}
------------------------------------------------------------------------------------------

To investigate the change in expression profile between hepatocellular carcinoma tissues and adjacent normal liver tissues and to explore the mechanisms that may be involved in hepatocarcinogenesis, we downloaded and analysed the gene expression profile of GSE33006 from the Gene Expression Omnibus -- a public functional genomics data repository (<http://www.ncbi.nlm.nih.gov/geo/>). The dataset, which was submitted by Huang *et al*. (2011), contains three HCC tissue chips and three adjacent normal liver tissue chips from patients who underwent surgery, and it is based on the Affymetrix GPL570 Platform (Affymetrix GeneChip Human Genome U133 Plus 2.0 Array). Total RNA was extracted from biopsied samples using TRIzol reagent for further individual on-chip analysis.

Screening of differentially expressed genes {#S20004}
-------------------------------------------

The original CEL files were downloaded and analysed using the R package (3.0.2) (<http://www.r-project.org/>). The robust multi-array average (RMA) method and Affymetrix Microarray Suite version 5 (MAS5) were used for data normalisation and background correcting. We used a classical t-test to identify differentially expressed genes with a variation \> 2-fold, and we defined *p* \< 0.05 to be statistically significant. The probe set ID list of selected differentially expressed genes was then uploaded to the NetAffx™ Analysis Centre (<http://Affymetrix.com/analysis/index/affx>) to obtain the corresponding gene symbols and gene titles. The expression data were deleted if there was no corresponding gene symbol for the probe set or if more than one gene symbol corresponded to a probe set. Only probe sets that mapped to a unique gene were suitable for further analysis. If there were multiple probe sets corresponding to the same gene, the expression values of these probe sets were then averaged.

Functional analysis of differentially expressed genes {#S20005}
-----------------------------------------------------

GenCLiP (a software program for clustering gene lists by literature profiling, and for constructing gene co-occurrence networks related to keywords of interest; <http://ci.smu.edu.cn/GenCLip/>) \[[@CIT0014], [@CIT0015]\] was used to analyse the differentially expressed genes, explore the pathogenesis, and construct gene networks related to important biological processes in tumours, such as metastasis, cell growth, and cell cycle progression.

Gene Ontology Analysis (GO) is a common useful approach for annotating genes and gene products and for predicting gene function for high-throughput genome or transcriptome data \[[@CIT0016], [@CIT0017]\]. To better investigate the function of these DEGs, a functional annotation tool, DAVID (Database for Annotation, Visualisation, and Integrated Discovery) v6.7 (<http://david.abcc.ncifcrf.gov/>), was used to cluster enriched function-related gene groups according to gene ontology (GO) terms, including molecular function, biological process, and cellular component \[[@CIT0018]\]. We also used DAVID to visualise genes on KEGG (Kyoto Encyclopaedia of Genes and Genomes) pathway maps to investigate the dysregulated biological pathways in which the DEGs may participate. The cut-off criteria were that a pathway must contain at least two differentially expressed genes and have a *p*-value \< 0.05.

Small molecule identification {#S20006}
-----------------------------

The Connectivity Map (CMap, build version build O2, <http://www.broadinstitute.org/cmap/>) was used to compare the differentially expressed genes with those in the CMap database, to identify the small molecules associated with these DEGs. First, we divided the DEGs into two groups with an upper limit of 500 probe sets per group: the up-regulated group and the down-regulated group. Then, the probe sets from the two groups were preloaded into their sandbox with the GRP format for gene set enrichment analysis. Finally, the enrichment scores, which ranged from +1 to --1, were calculated.

The enrichment value represented the association between the preloaded query signature and the gene profile for a small molecule treatment. A high positive up score (close to +1) indicates that the corresponding small molecule induces the expression of the probe sets in the up tag list (hepatocellular carcinoma), whereas a high negative up score (close to --1) indicates greater similarity between the genes induced by the small molecule and the probe sets in the down tag list (adjacent normal liver).

Results {#S0007}
=======

Identification of differentially expressed genes {#S20008}
------------------------------------------------

Using bioinformatics analysis we found 4233 probe set IDs that differed between the HCC and adjacent normal liver tissues. After the gene symbols from Affymetrix database were matched and the substandard expression data were removed, altered expression was identified for 2721 probe set IDs (corresponding to 2721 genes); these genes were marked for further analysis.

GenCLiP analysis of the differentially expressed genes {#S20009}
------------------------------------------------------

Of the 2721 analysed genes, 2701 had related literature, with an average of 661 literature matches per gene; these genes were subsequently used for cluster analysis ([Fig. 1](#F0001){ref-type="fig"}).

![Literature profiling of differentially expressed genes. Clustergram generated from analysing the keyword occurrence of the analysed genes. Green represents the corresponding gene-term associations that were reported to be positive](WO-20-27106-g001){#F0001}

We used the "literature mining gene networks" function of GenCLiP to search for related genes and to construct co-occurrence gene networks among the DEGs using the keyword "metastasis". A total of 180 known metastasis-related genes were identified, and 180 genes formed 268 related gene pairs ([Fig. 2A](#F0002){ref-type="fig"}). To determine whether the 180 known metastasis-related genes were identified randomly, PubMed was used to search for the occurrence of each gene set of the microarray with the keyword "metastasis", and then 300 random simulations were performed. The resulting distribution of the number of metastasis-related genes and gene pairs derived from random genes was similar to the normal distribution, and the probability that a set of 2701 randomly selected genes contained more than 180 metastasis-related genes or 268 gene pairs was *p* = 0.00000 for both distributions ([Fig. 2B](#F0002){ref-type="fig"}). Furthermore, gene networks related to the keywords "cell growth" and "cell cycle" were also constructed (Supplement Fig. S1).

![Constructing a gene co-occurrence network related to the keyword "metastasis" from the differentially expressed genes. A) The network of analysed genes. The orange node represents known hepatocellular carcinoma-related genes. B) The distribution of the number of metastasis-related genes and gene pairs derived from the random genes was similar to the normal distribution](WO-20-27106-g002){#F0002}

Gene Ontology analysis of differentially expressed genes {#S20010}
--------------------------------------------------------

These 2721 differentially expressed genes were functionally classified into three Gene Ontology (GO) categories using the online analysis tool DAVID. For the biological process category, a cut-off level of *p* \< 0.001 was used to identify significant enrichment of genes with the corresponding GO terms. Analysis revealed changes in the biological processes of the immune system, such as the positive regulation of immune system processes, leukocyte activation, innate immune response, T cell activation, B cell-mediated immunity, and immunoglobulin-mediated immune response. The DEGs also showed significant enrichment in processes related to the regulation of cell growth, such as the regulation of cell proliferation, the cell cycle, cell differentiation, nuclear division, and M phase of the mitotic cell cycle. Changes in the expression profile also affected the biological processes of angiogenesis and signal transduction ([Table 1](#T0001){ref-type="table"}).

###### 

Gene Ontology enrichment of differentially expressed genes in biological process

  Term                                                                                                               Count   *p*-value
  ------------------------------------------------------------------------------------------------------------------ ------- -----------
  GO:0006955∼immune response                                                                                         182     9.01E-18
  GO:0002376∼immune system process                                                                                   239     1.60E-17
  GO:0002526∼acute inflammatory response                                                                             49      2.01E-16
  GO:0006952∼defense response                                                                                        157     7.08E-14
  GO:0048518∼positive regulation of biological process                                                               402     1.34E-13
  GO:0002460∼adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin   39      2.32E-13
  GO:0002682∼regulation of immune system process                                                                     110     3.04E-13
  GO:0002541∼activation of plasma proteins involved in acute inflammatory response                                   27      3.09E-12
  GO:0045087∼innate immune response                                                                                  53      6.50E-12
  GO:0002449∼lymphocyte-mediated immunity                                                                            35      7.52E-12
  GO:0019724∼B cell-mediated immunity                                                                                30      3.50E-11
  GO:0016064∼immunoglobulin-mediated immune response                                                                 29      7.34E-11
  GO:0002455∼humoral immune response-mediated by circulating immunoglobulin                                          20      1.96E-09
  GO:0022610∼biological adhesion                                                                                     152     5.46E-08
  GO:0007155∼cell adhesion                                                                                           151     8.58E-08
  GO:0042110∼T-cell activation                                                                                       41      4.11E-07
  GO:0008283∼cell proliferation                                                                                      98      3.28E-06
  GO:0045595∼regulation of cell differentiation                                                                      107     5.46E-06
  GO:0001944∼vasculature development                                                                                 62      1.37E-05
  GO:0050848∼regulation of calcium-mediated signalling                                                               12      2.32E-05
  GO:0001568∼blood vessel development                                                                                59      4.95E-05
  GO:0007049∼cell cycle                                                                                              150     5.66E-05
  GO:0007059∼chromosome segregation                                                                                  25      2.69E-04
  GO:0009966∼regulation of signal transduction                                                                       162     3.13E-04
  GO:0007169∼transmembrane receptor protein tyrosine kinase signalling pathway                                       52      3.76E-04
  GO:0000087∼M phase of mitotic cell cycle                                                                           52      3.76E-04
  GO:0040011∼locomotion                                                                                              88      3.93E-04
  GO:0007067∼mitosis                                                                                                 51      4.46E-04
  GO:0007167∼enzyme linked receptor protein signalling pathway                                                       72      5.78E-04
  GO:0006928∼cell motion                                                                                             94      7.27E-04
  GO:0001525∼angiogenesis                                                                                            37      7.33E-04
  GO:0040007∼growth                                                                                                  43      9.98E-04

In the category of cellular component, the most enriched GO term was cytoplasm (1089 genes). In addition, the DEGs were also enriched in cellular components related to the plasma membrane, extracellular region, chromosome, secretory granules, and the cytoplasmic membrane-bound vesicle lumen (*p* \< 0.01) ([Table 2](#T0002){ref-type="table"}). [Table 3](#T0003){ref-type="table"} shows the clustered GO terms in the molecular function category for the differentially expressed genes (*p* \< 0.01). The HCC expression profile indicated that the activity of some enzymes changed, including the activities of oxidoreductase, endopeptidase inhibitor, transmembrane receptor protein tyrosine kinase, etc. The binding abilities of some materials (polysaccharides, glycosaminoglycans, etc.) were also changed.

###### 

Gene Ontology enrichment of differentially expressed genes in cellular component

  Term                                                    Count   *p*-value
  ------------------------------------------------------- ------- -----------
  GO:0044421∼extracellular region part                    212     2.83E-13
  GO:0005615∼extracellular space                          160     3.50E-12
  GO:0031226∼intrinsic to plasma membrane                 248     1.60E-11
  GO:0005887∼integral to plasma membrane                  242     3.67-11
  GO:0005576∼extracellular region                         366     8.21E-11
  GO:0009897∼external side of plasma membrane             52      2.24E-08
  GO:0009986∼cell surface                                 86      3.78E-08
  GO:0031093∼platelet alpha granule lumen                 21      7.13E-08
  GO:0060205∼cytoplasmic membrane-bounded vesicle lumen   21      3.09E-07
  GO:0031983∼vesicle lumen                                21      7.49E-07
  GO:0000793∼condensed chromosome                         37      1.54E-05
  GO:0005737∼cytoplasm                                    1089    2.58E-05
  GO:0005886∼plasma membrane                              593     2.81E-05
  GO:0005579∼membrane attack complex                      7       4.00E-05
  GO:0043235∼receptor complex                             32      1.41E-04
  GO:0005694∼chromosome                                   91      2.32E-04
  GO:0030141∼secretory granule                            43      2.92E-04
  GO:0044433∼cytoplasmic vesicle part                     41      0.0024
  GO:0005604∼basement membrane                            21      0.0034
  GO:0000777∼condensed chromosome kinetochore             17      0.0039
  GO:0031012∼extracellular matrix                         66      0.0041
  GO:0000775∼chromosome, centromeric region               29      0.0046
  GO:0031410∼cytoplasmic vesicle                          112     0.0048
  GO:0034358∼plasma lipoprotein particle                  12      0.0054
  GO:0000779∼condensed chromosome, centromeric region     18      0.0064
  GO:0030055∼cell-substrate junction                      26      0.0082

###### 

Gene Ontology enrichment of differentially expressed genes in molecular function

  Term                                          Count   *p*-value
  --------------------------------------------- ------- -----------
  GO:0005515∼protein binding                    1282    5.58E-10
  GO:0030247∼polysaccharide binding             49      4.16E-08
  GO:0005539∼glycosaminoglycan binding          45      1.15E-07
  GO:0030246∼carbohydrate binding               87      1.71E-07
  GO:0003823∼antigen binding                    20      1.46E-04
  GO:0008201∼heparin binding                    30      1.49E-04
  GO:0019955∼cytokine binding                   31      1.80E-04
  GO:0019838∼growth factor binding              30      2.14E-04
  GO:0046983∼protein dimerization activity      105     5.49E-04
  GO:0030234∼enzyme regulator activity          151     0.001
  GO:0004896∼cytokine receptor activity         18      0.0011
  GO:0019825∼oxygen binding                     15      0.0017
  GO:0004866∼endopeptidase inhibitor activity   35      0.0017
  GO:0030414∼peptidase inhibitor activity       36      0.0023
  GO:0004497∼monooxygenase activity             25      0.0037
  GO:0003824∼catalytic activity                 787     0.0051
  GO:0019899∼enzyme binding                     96      0.0052
  GO:0019842∼vitamin binding                    30      0.0074
  GO:0019901∼protein kinase binding             33      0.0074
  GO:0008172∼S-methyltransferase activity       5       0.0097
  GO:0016491∼oxidoreductase activity            120     0.0099

KEGG pathway enrichment analysis {#S20011}
--------------------------------

The changed gene expression profile of hepatocellular carcinoma may result in many dysregulated signal pathways. We used DAVID to cluster the DEGs for KEGG pathway enrichment analysis, and *p* \< 0.05 was set as the cut-off criteria for statistical significance. As shown in [Table 4](#T0004){ref-type="table"}, 20 dysregulated pathways were identified from the changes in HCC; of these pathways, the complement and coagulation cascades and cell adhesion molecules (CAMs) showed the most significant enrichment (*P* = 2.79E-18 and *P* = 3.17E-04, respectively). As previously reported, some altered pathways were highly related to the initiation or progression of malignant tumours; these pathways included the TGF-β signalling pathway, T cell/B cell receptor signalling pathway, and pathways related to DNA replication and cytokine-cytokine receptor interactions.

###### 

The altered KEGG pathways

  Term       Description                                    Count   *p*-value
  ---------- ---------------------------------------------- ------- -----------
  hsa04610   complement and coagulation cascades            44      2.79E-18
  hsa04514   cell adhesion molecules (CAMs)                 38      3.17E-04
  hsa00071   fatty acid metabolism                          15      0.0027
  hsa04640   hematopoietic cell lineage                     25      0.0037
  hsa00380   tryptophan metabolism                          14      0.0077
  hsa04672   intestinal immune network for IgA production   16      0.0081
  hsa04060   cytokine-cytokine receptor interaction         58      0.0084
  hsa04660   T cell receptor signalling pathway             28      0.011
  hsa04110   cell cycle                                     31      0.013
  hsa00330   arginine and proline metabolism                16      0.017
  hsa05214   glioma                                         18      0.019
  hsa03030   DNA replication                                12      0.022
  hsa04512   ECM-receptor interaction                       22      0.023
  hsa00590   arachidonic acid metabolism                    16      0.028
  hsa04350   TGF-β signalling pathway                       22      0.033
  hsa04810   regulation of actin cytoskeleton               46      0.034
  hsa05322   systemic lupus erythematosus                   24      0.040
  hsa00280   valine, leucine, and isoleucine degradation    13      0.041
  hsa04662   B cell receptor signalling pathway             19      0.048
  hsa04650   natural killer cell mediated cytotoxicity      30      0.049

Identification of candidate small molecules {#S20012}
-------------------------------------------

To identify candidate small molecules that could reverse the gene expression changes of hepatocellular carcinoma, the DEGs were divided into two groups: up-regulated and down-regulated, which were uploaded to the CMap database for Gene Set Enrichment Analysis and then matched to treatments with small molecules. The 20 most significant small molecules are listed in [Table 5](#T0005){ref-type="table"} with their enrichment scores and p-values. As shown in [Table 5](#T0005){ref-type="table"}, the small molecules vorinostat (enrichment score = 0.973) and trichostatin A (enrichment score = 0.895) were associated with a highly significant positive score and could partially imitate the status of hepatocellular carcinoma. These small molecules may be strong induction factors for HCC. In contrast, cromoglicic acid (enrichment score = --0.927) and ranitidine (enrichment score = --0.837) were associated with highly significant negative scores and may imitate the normal liver status. These small molecules could reverse the tumoral status of HCC and therefore provide novel ideas and molecular mechanisms for developing new drugs for treating HCC in the future. However, these candidate small molecules still require further detailed research.

###### 

List of top 20 identified small molecules

  Cmap name                   Enrichment score   *p*-value
  --------------------------- ------------------ -----------
  vorinostat                  0.973              0
  trichostatin A              0.895              0
  geldanamycin                0.705              0
  fluphenazine                0.629              0
  trifluoperazine             0.625              0
  thioridazine                0.599              0
  sirolimus                   0.491              0
  valproic acid               0.359              0
  pioglitazone                --0.646            0.00004
  6-bromoindirubin-3'-oxime   --0.769            0.00008
  withaferin A                0.896              0.0001
  wortmannin                  0.501              0.0001
  ivermectin                  0.858              0.00012
  prochlorperazine            0.524              0.00014
  suloctidil                  0.888              0.00016
  cephaeline                  0.848              0.00018
  PNU-0293363                 --0.954            0.00022
  ranitidine                  --0.837            0.0003
  meptazinol                  --0.825            0.00177
  betahistine                 --0.822            0.00189

Discussion {#S0013}
==========

By analysing the differentially expressed genes using GenCLiP software, 180 metastasis related genes were identified and used to construct co-occurrence gene networks. Of the metastasis-related genes, *TGFB1* and *EGFR* had the largest number of co-occurring genes (34 and 33, respectively) and were located in the centre of the network. As recognised dysregulated growth factors, TGFB1/EGFR and their downstream signalling pathway components contribute to the proliferation and invasive behaviour of liver cancer cells \[[@CIT0019]--[@CIT0021]\]. As a transmembrane glycoprotein, CD44 was shown to interact with 28 genes. Reports have revealed that through the interaction of CD44 and its association molecules, CD44 can regulate cancer cell proliferation, adhesiveness, migration, and metastasis \[[@CIT0022]\]. CD44 was also demonstrated to be closely associated with the extrahepatic metastasis of HCC \[[@CIT0023]\]. Co-occurrence networks involving large numbers of related genes enable researchers to identify critical genes and their possible interactional networks, which may provide a new direction for the diagnosis and targeted therapy of HCC.

Gene Ontology (GO) analysis revealed that these DEGs were closely related to multiple biological processes involved in the mechanism of most malignant tumours, such as the regulation of the immune system, cell growth, the cell cycle, angiogenesis, and signal transduction. Several significant altered pathways were identified by KEGG pathway analysis. The TGF-β signal pathway has been reported to be functionally impaired in hepatocarcinogenesis \[[@CIT0020]\]. Interactions between the extracellular matrix (ECM) receptor and cells play a vital role in cell adhesion and form a crucial step in tumour cell migration and invasion into the extracellular matrix \[[@CIT0024]\].

Analysis using the CMap database identified a set of small molecules that may imitate the status of hepatocellular carcinoma or a normal liver. The candidate small molecules that were associated with highly significant negative enrichment scores may reverse the abnormal gene expression profile of HCC; this information will be beneficial to investigators who may develop new target therapeutic drugs against HCC. Histamine has been demonstrated to be involved in cell proliferation and tumour growth by the activation of histamine receptors \[[@CIT0025]\]. As an agonist of histamine that interacts with the H1 and H3 receptors \[[@CIT0026]\], betahistine may play a role in tumour biology through the regulation of histamine receptors.

In conclusion, we identified 2271 differentially expressed genes in hepatocellular carcinoma, and the co-occurrence networks related to "metastasis", "cell growth", and "cell cycle" were constructed. Furthermore, we identified significant biological processes and abnormally altered pathways that were related to the development of HCC. We also screened a set of candidate small molecules, some of which may induce the initiation of HCC, and some reversed the expression profile of HCC. These small molecules may be candidates for therapeutic drugs that are capable of targeting hepatocellular carcinoma. However, the number of samples involved in this study was limited, and the analysed results contained a massive amount of information, which requires thorough research and must be experimentally validated in future studies.
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